Teva Pharmaceuticals
TEVA
818 hedge funds and large institutions have $30.6B invested in Teva Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 260 increasing their positions, 327 reducing their positions, and 82 closing their positions.
36% more call options, than puts
Call options by funds: $692M | Put options by funds: $508M
6% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 82
0% less funds holding
Funds holding: 821 → 818 (-3)
0.6% less ownership
Funds ownership: 54.6% → 54% (-0.6%)
6% less capital invested
Capital invested by funds: $32.5B → $30.6B (-$1.96B)
20% less repeat investments, than reductions
Existing positions increased: 260 | Existing positions reduced: 327
33% less funds holding in top 10
Funds holding in top 10: 70 → 47 (-23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$550M |
| 2 |
SC
Sculptor Capital
New York
|
+$226M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$175M |
| 4 |
SIG
Senator Investment Group
New York
|
+$142M |
| 5 |
PC
Paulson & Co
New York
|
+$125M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$412M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$340M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$304M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$196M |
| 5 |
Lazard Asset Management
New York
|
-$154M |
TEVA Hedge Fund Activity: Q2 2015 in Review
818 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2015, worth a combined $30.6B — down 6% from $32.5B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new TEVA positions and 82 closed out — a net gain of 5 holders — while 260 added to existing stakes and 327 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $550M. The largest seller was Millennium Management, cutting an estimated $412M.
- 818 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2015, down from 821 in Q1 2015.
- Funds reported $30.6B of Teva Pharmaceuticals stock for Q2 2015, down 6% quarter-over-quarter.
- 87 funds opened new Teva Pharmaceuticals positions in Q2 2015 and 82 closed out, a net change of +5 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2015 was Fidelity Investments, an estimated $550M added.
- The largest Teva Pharmaceuticals seller in Q2 2015 was Millennium Management, an estimated $412M sold.
Based on aggregated 13F filings for Q2 2015.